Published Special Issue
Volume 3, Issue 2-1
Expired Date:
Jan. 30, 2015
Order the Hard Copy
Special Issues
Expand the Popularity of Your Conference
Publish conference papers as a Special Issue
Send your Special Issue proposal to:
Submit Hot Topics
If you wish to order hard copies, please click here to know more information.
Lead Guest Editor:
Professor Julius Oloke
Department of Microbiology and Immunology, All Saint University, St Vincent, Saint Vincent and the Grenadines
Paper List
Authors: Yemisi Olukemi Adesiji, Julius Kola Oloke
Pages: 1-7 Published Online: Feb. 7, 2015
Views 2992 Downloads 151
Authors: Oloke J. K., Adebayo E. A.
Pages: 8-20 Published Online: Feb. 7, 2015
Views 3842 Downloads 188
The aim of this special issue titled " Immunotherapy" is to enhance effective health care delivery by giving researchers opportunity to share their recent findings in the stimulation of immune system .

Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapy

The active agents of immunotherapy are collectively called immunomodulators. They are diverse array of recombinants, synthetic and natural preparations, often cytokines. Some of these substances, such as granulocyte colony-stimulating factor, interferon, imiquimod and cellular membrane fractions from bacteria are already licensed for use in patens. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine oligodeoxynucleotides and glucans are currently been investigated in clinical and preclinical studies.

Immunomodulatory regimes offer an attractive approach as they often have fewer side effects than the existing drugs, including less potential for creating resistance in microbial disease. Immune effector cells such as lymphocytes, macrophages dendritic cells, natural killer cells, cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of the tumor due to mutation.

For this special issue; researchers are encouraged to send in their manuscripts covering the following topics:

1. Autologous immune enhancement therapies
2. Vaccination
3. Cancer immunotherapy
4. Immunosuppressive drugs
5. Allergen immunotherapy
6. Helminthic therapies
7. Genetically engineered T cells
8. T cell adoptive transfer
9. Dendritic cell-based immunotherapy
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186